

February 6, 2007



GelStat Receives Notice of Allowance for U.S. Patent for Its GelStat(TM) Migraine Product

ST. PAUL, MN -- (MARKET WIRE) -- 02/06/07 -- elStat Corporation (PINKSHEETS: GSAC), a consumer healthcare company primarily focused on the development and marketing of over-the-counter (OTC) products for the safe and effective treatment of pain and inflammation, is pleased to announce that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering the use of its proprietary over-the-counter product, GelStat(TM) Migraine, to treat migraine headaches.

The patent application, entitled "Compositions and Methods of Treatment to Alleviate or Prevent Migrainous Headaches and Their Associated Symptoms," includes a number of key claims surrounding the Company's product formulation and its sublingual (under the tongue) delivery. GelStat Migraine is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. It is estimated that 30 million Americans suffer from migraine.

Commenting on the news, James LaFlamme, GelStat's Chairman said, "We believe the Notice of Allowance announced today represents a significant increase in the value of GelStat's intellectual property portfolio. It forms the basis for our GelStat Migraine product, as well as laying the foundation for future related work in treating other pain and inflammation related disorders. The corresponding patent should be issued within the next several months, and we are very pleased with the opportunities this new patent provides."

ABOUT GELSTAT CORPORATION

GelStat Corporation is dedicated to providing safe and effective over-the-counter (OTC) treatments for pain and inflammation. GelStat's first product, GelStat Migraine, is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. GelStat Migraine is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 30 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs. Americans spend \$2.6 billion each year on 600 million units of such products, although they are believed to be effective for only about 25 percent of those with moderate to severe migraine.

Click the following links to view supporting information on the effectiveness of GelStat Migraine:

[Initial Clinical Trial of GelStat Migraine Shows it to be Effective for 83 Percent of those with Moderate to Severe Migraine](#)

[GelStat is Effective in Relieving Migraine Pain in a Double-Blind, Placebo-Controlled study](#)

[2 Minute Video Demonstrating the Product and its Successful Treatment of a Migraine Headache](#)

The Company also has a suite of additional, effective healthcare products that address large consumer markets. GelStat(TM) Arthritis is the second available product to utilize GelStat's patent pending formulation and is provided as a daily use, sublingual dissolving tablet. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans. The Company has also developed "GelStat(TM) Sinus" and "GelStat(TM) Sleep," and believes that each of these products performs well and is effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be "problem sleepers."

For more information, visit www.gelstat.com

Safe Harbor Statement Under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of GelStat could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors, please review our SEC filings.

CONTACT:

Redwood Consultants, LLC
415-884-0348

investorinfo@redwoodconsultants.com